TY - JOUR
T1 - Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers
AU - Sablerolles, Roos S. G.
AU - Rietdijk, Wim J. R.
AU - Goorhuis, Abraham
AU - Postma, Douwe F.
AU - Visser, Leo G.
AU - Schmitz, Katharina S.
AU - Geers, Daryl
AU - Bogers, Susanne
AU - van Haren, Eva
AU - Koopmans, Marion P. G.
AU - Dalm, Virgil A. S. H.
AU - Kootstra, Neeltje A.
AU - Huckriede, Anke L. W.
AU - Akkerman, Renate
AU - Beukema, Martin
AU - Lafeber, Melvin
AU - SWITCH Research Group
AU - van Baarle, Debbie
AU - de Vries, Rory D.
AU - van der Kuy, P. Hugo M.
AU - GeurtsvanKessel, Corine H.
N1 - Funding Information: The SWITCH trial was funded by a grant (10430072110001) from ZonMw. Publisher Copyright: © 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.
AB - The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.
KW - Ad26.COV2.S
KW - SARS-CoV-2
KW - waning immunity
UR - http://www.scopus.com/inward/record.url?scp=85147783363&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/cid/ciac495
DO - https://doi.org/10.1093/cid/ciac495
M3 - Article
C2 - 35723273
SN - 1058-4838
VL - 76
SP - e533-e536
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 3
ER -